The tumour suppressor gene, AIMP3, sensitises bladder cancer to chemo/radiotherapy in vitro and is, with ERCC1, a predictive marker of overall survival in patients treated with radical radiotherapy for muscle-invasive disease
Bladder cancer is the second most common urological cancer after prostate cancer and is one of the leading causes of cancer mortality in most western countries. For organ-confined, muscle-invasive disease, the standard of care, in terms of definitive cure, remains radical surgery (cystectomy) with l...
| Main Author: | |
|---|---|
| Published: |
University College London (University of London)
2015
|
| Subjects: | |
| Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.639681 |